Kensei Yamaguchi, MD, Cancer Institute Hospital of JFCR, Tokyo, Japan, discusses results from DESTINY-Gastric 01 (NCT03329690), a Phase II study investigating trastuzumab deruxtecan (T-DXd) in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).